Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
atrasentan - ETA receptor antagonist
Company overview
Financial review
Conclusions
NCT04573478 ALIGN (CHK01-01)
Indication
Phase
Patients
Outcome
Measures
Arms
Intervention
Target Patients
IgA nephropathy
Phase 3
380
Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated
over 24 months
Arm 1 Experimental: Atrasentan, once daily oral administration of 0.75 mg
atrasentan for 132 weeks
Arm 2 Placebo comparator: Placebo once daily oral administration of placebo for
132 weeks
Patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function
2023 (primary endpoint for US initial submission)
2026 (24 months)
Readout
Milestone(s)
Publication
TBD
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
> Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
Primary
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
47View entire presentation